$46.26 0.76 (+1.67%)
11/6/2009 4:00 PM

Gilead Sciences, Inc. (GILD)

CAPS Rating: 5 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Recs

1
Member Avatar corcione (57.84) Submitted: 5/11/2009 7:30:02 AM : Outperform Start Price: $43.97 GILD Score: -12.83

Gilead is a leader in HIV treatment and the company also receives royalties from Roche for Tamiflu, a treatment for
influenza. The new US administration is committed to increase spending for HIV diagnosis and treatment.
Generic drug competition will clearly weigh on pharma, but Gilead's superior market positioning is worth paying for.

Report this Post 0 Comments

Featured Broker Partners